Completed PHASE1 INTERVENTIONAL 1-arm NCT02101580

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer

Sponsor: Polaris Group

Interventions ADI-PEG 20

Updated 9 times since 2017 Last updated: Sep 30, 2020 Started: Nov 17, 2014 Primary completion: May 5, 2017 Completion: Oct 6, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02101580, this PHASE1 trial focuses on Advanced Pancreatic Cancer and remains completed. Sponsored by Polaris Group, it has been updated 9 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Oct 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Terminated → Completed
Apr 2020 — Oct 2020 [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated

▶ Show 4 earlier versions

Apr 2019 — Apr 2020 [monthly]

Active Not Recruiting PHASE1
Jun 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE1
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Polaris Group

Data source: Polaris Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States